Bortezomib in multiple myeloma: treatment and retreatment. A single center experience.
Warzocha
Krzysztof
K
Institute of Hematology and Transfusion Medicine, 14 Indira Gandhi St., 02-776 Warsaw, Poland.
Kraj
Maria
M
Pogłód
Ryszard
R
Kwaśniak
Beata
B
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D003907:Dexamethasone / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007952:Leukemia, Plasma Cell / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D009364:Neoplasm Recurrence, Local; D011719:Pyrazines / Q000008:administration & dosage; D016896:Treatment Outcome
D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib; D003907:Dexamethasone; D004317:Doxorubicin